The DOI matches its Crossref record.
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
Abstract
The pharmacokinetics of cyclosporine was studied in six healthy volunteers after administration of the drug orally (10 mg/kg) and intravenously (3 mg/kg) with and without concomitant rifampin administration. Both blood and plasma (separated at 37 degrees C) samples were analyzed for cyclosporine concentration. For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase. Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively. Rifampin not only induces the hepatic metabolism of cyclosporine but also decreases its bioavailability to a greater extent than would be predicted by the increased metabolism. The decreased bioavailability most probably can be explained by an induction of intestinal cytochrome P450 enzymes, which appears to be markedly greater than the induction of hepatic metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
Self-citationHumanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Self-citationIto, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Population-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338
King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., & Marshall, M. S. (1998) · Nature · doi:10.1038/24184 · Cited by 443
Wacher, V. J., Silverman, J. A., Zhang, Y., & Benet, L. Z. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980082d · Cited by 423
Self-citationGorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
Watkins, P. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00041-0 · Cited by 391
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., & Wacher, V. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90168-x · Cited by 356
Self-citationEmerging Trends in Oral Delivery of Peptide and Protein Drugs
Mahato, R. I., Narang, A. S., Thoma, L., & Miller, D. D. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i23.30 · Cited by 352
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*
Ducharme, M. P., Warbasse, L. H., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90032-2 · Cited by 347
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
Varma, M. V. S., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 331
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.741 · Cited by 325
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Drug–drug interaction mediated by inhibition and induction of P-glycoprotein
Lin, J. H. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00171-0 · Cited by 309
Active secretion and enterocytic drug metabolism barriers to drug absorption
Wacher, V. J., Salphati, L., & Benet, L. Z. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00127-s · Cited by 308
Self-citationFirst-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 302
Oral chemotherapy: rationale and future directions.
DeMario, M. D., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2557 · Cited by 293
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., & Wacher, V. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00034-6 · Cited by 292
Self-citationThe Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Hebert, M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00043-4 · Cited by 288
Self-citationInterindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes
Lin, J. H., & Lu, A. Y. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 285
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
Self-citationRecent Advances: the Cytochrome P450 Enzymes
Slaughter, R. L., & Edwards, D. J. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900612 · Cited by 274
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*
Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P., & Hebert, M. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90150-8 · Cited by 268
Self-citationSchuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
CYP induction-mediated drug interactions: in vitro assessment and clinical implications
Lin, J. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0277-7 · Cited by 264
TSUNODA, S., VELEZ, R., VONMOLTKE, L., & GREENBLATT, D. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70009-3 · Cited by 257
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
TANNERGREN, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.012 · Cited by 138
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Self-citationKomura, H., & Iwaki, M. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.597401 · Cited by 78
Clearance Concepts: Fundamentals and Application to Pharmacokinetic Behavior of Drugs
Mehvar, R. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29896 · Cited by 39
“(26), who administered a single oral (10 mg/kg) or intravenous (3 mg/kg) dose of cyclosporine to six healthy subjects and found average blood AUC values of 8986 and 10092 ng.”
Background
Metadata
- Authors
- Hebert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-11
- Volume
- 52
- Issue
- 5
- Pages
- 453-457
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2059588998
- Cited by
- 337
- References
- 0
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.